Scancell progresses its new anti-glycan monoclonal antibody (mAb) platform GlyMab™
Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: “We believe our proprietary GlyMab™ platform provides a powerful and versatile approach to generating novel antibody drug candidates that bind to sugar motifs, rather than peptide epitopes, found on the surface of glycosylated proteins and lipids that are implicated as drug targets in particular cancers and potentially other diseases. As such, this new platform expands on Scancell’s unique approach to developing innovative therapies for cancer and infectious disease. The Board believes that there are multiple ways to maximise the value of these innovative and proprietary assets, either developing them internally to further value inflection points, develop alongside strategic partners or through earlier stage commercial licences. The fourth research agreement on the Glymab™ platform provides further validation of the commercial potential of this platform.”
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib